Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
Arcus (RCUS) Q2 Revenue Jumps 310%
11:05pm, Wednesday, 06'th Aug 2025
Arcus (RCUS) Q2 Revenue Jumps 310%
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
07:11pm, Wednesday, 06'th Aug 2025
Arcus Biosciences, Inc. (RCUS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.02 per share a year ago.
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Thursday, 24'th Jul 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
08:30am, Thursday, 10'th Jul 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Wednesday, 09'th Jul 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 24'th Jun 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
03:36am, Wednesday, 11'th Jun 2025
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% during the 4th quarter, according to the
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 10'th Jun 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 27'th May 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Friday, 09'th May 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript
08:17pm, Tuesday, 06'th May 2025
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob G
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
07:10pm, Tuesday, 06'th May 2025
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago.
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Thursday, 24'th Apr 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
04:05pm, Tuesday, 22'nd Apr 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
